Big pharma Bristol-Myers Squibb’s (BMY) cancer drug Opdivo continued to shine Friday, as the company halted another clinical trial early because it had already hit its endpoint. The phase-three trial, called Checkpoint-057, compared Opdivo in advanced non-squamous non-small-cell lung cancer with standard treatment docetaxel (better known as Sanofi’s (SNY) Taxotere). The study found a significant improvement in overall survival in the Opdivo arm,
Small biotech Amicus Therapeutics (FOLD) jumped more than 30% Thursday after the company said it would file for accelerated approval of its lead drug candidate after positive meetings with the FDA and EU authorities. Amicus’ drug migalastat would be the first oral treatment for Fabry disease, a rare but serious congenital condition currently treated with the IV drugs Fabrazyme (from Sanofi (SNY) and Replagal (from Shire (SHPG). Amicus said that
Akorn (AKRX) shares made big gains in the stock market today. The drugmaker had to restate its Q2 and Q3 2014 financial statements because of an error that led to an overstatement of revenue and earnings in Q2. But investors seem to be relieved by the move. Watch this video for a breakdown of this highly rated stock’s chart action. Other drug stocks that moved on big news this week include Regeneron (REGN), Amgen (AMGN), Sanofi (SNY), Esperion